GlassScriptPhysician profile
Robert V Salzman
NPI 1629686845
$6,344.22
in general payments reported to CMS, 2019-2025
30 companies · $2,999 in 2025
The $2,999 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $997 · 2024: $2,348 · 2025: $2,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,890 · Education: $429 · Consulting Fee: $24.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,889.94 |
| Education | $429.39 |
| Consulting Fee | $24.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,080.04 | 2023-2025 | Dupixent |
| Csl Behring | $1,014.08 | 2023-2025 | Haegarda, Andembry, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $904.76 | 2023-2025 | Cuvitru, Takhzyro, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $844.30 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $595.41 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $277.14 | 2023-2025 | |
| Glaxosmithkline, LLC. | $242.14 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pharming Healthcare, INC. | $179.05 | 2023-2025 | Ruconest |
| Pfizer INC. | $138.16 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $116.54 | 2023-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Lilly USA, LLC | $98.95 | 2024-2025 | Ebglyss |
| Genentech USA, INC. | $95.90 | 2023-2025 | Xolair |
| Amgen INC. | $90.14 | 2023-2025 | Tezspire |
| Optinose US, INC. | $67.57 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gc Biopharma USA, INC. | $55.84 | 2025 | Alyglo |
| Galderma Laboratories, L.P. | $55.16 | 2025 | Nemluvio |
| Organon LLC | $54.83 | 2025 | |
| Ionis Pharmaceuticals, INC. | $49.30 | 2025 | Dawnzera |
| Grifols USA, LLC | $42.67 | 2023-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $37.33 | 2025 | Neffy |
| Azurity Pharmaceuticals, INC. | $35.97 | 2025 | Alvesco |
| Incyte Corporation | $29.76 | 2025 | Opzelura |
| Adma Biomanufacturing LLC | $24.89 | 2025 | |
| Leo Pharma INC. | $23.65 | 2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $22.90 | 2025 | Zoryve |
| Tersera Therapeutics LLC | $18.43 | 2023 | Quzyttir |
| Paratek Pharmaceuticals, INC. | $18.28 | 2025 | Xhance |
| X4 Pharmaceuticals, INC. | $17.23 | 2025 | Xolremdi |
| Hikma Pharmaceuticals USA | $14.81 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Salzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.